| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm | 44.75 mm |
| Cash burn (monthly) | 3.88 mm | 4.63 mm | 6.77 mm | 5.29 mm | 3.79 mm | 4.59 mm |
| Cash used (since last report) | 89.48 mm | 106.94 mm | 156.33 mm | 122.14 mm | 87.43 mm | 106.02 mm |
| Cash remaining | -44.73 mm | -62.19 mm | -111.58 mm | -77.39 mm | -42.68 mm | -61.27 mm |
| Runway (months of cash) | -11.5 | -13.4 | -16.5 | -14.6 | -11.3 | -13.3 |
| 13F holders | Current |
|---|---|
| Total holders | 4 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 43.18 mm |
| Total shares | 20.66 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Bain Capital Life Sciences Fund | 8.07 mm | $24.12 mm |
| Artal International S.C.A. | 6.12 mm | $0.00 |
| New Leaf Ventures III | 3.29 mm | $8.79 mm |
| Frazier Life Sciences VIII | 3.19 mm | $10.27 mm |
